By Justin Petrone
Affymetrix will initiate clinical trials for its CytoScan HD cytogenetics array in March, and hopes to submit the assay to the US Food and Drug Administration for clearance by the middle of this year, according to its CEO.
Frank Witney discussed the firm's plans during the JP Morgan Healthcare Conference in San Francisco last week. A company spokesperson this week confirmed the firm's plans but declined to further discuss its dealings with the FDA.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.